Personalized mRNA cancer vaccine shows promise in late-stage trials

Results from a Phase III clinical trial of a personalized mRNA vaccine developed by Moderna and Merck, in combination with pembrolizumab, represent a significant step forward in personalized cancer treatment. This marks the first time the effectiveness of such an individualized therapy has been confirmed in an advanced clinical trial phase.

Pembrolizumab, a drug used for about a decade in melanoma patients for palliative or supplementary care, is now being combined with the novel mRNA vaccine. The study focused on patients with high-risk melanoma whose cancer had been completely removed through surgery. The findings demonstrated a significant extension in the time patients remained disease-free and free from distant metastases, highlighting new possibilities for mRNA technology in oncology.

Experts suggest that based on these positive Phase III results, regulatory submission applications could be filed in the near future. They anticipate that this personalized vaccine might become available to patients outside of clinical trials within the next one to two years. Unlike mRNA vaccines used for mass prevention, such as those for COVID-19, this cancer vaccine is a form of adjuvant treatment designed to reduce the risk of recurrence in patients who have had their tumors surgically removed.

The vaccine works by preparing a patient's immune system to fight any remaining cancer cells. It contains information about mutated proteins, known as neoantigens, which are intended to strongly stimulate an immune response specifically targeted at cancer cells. The need for individual preparation stems from the genetic diversity of cancers; even the same type of tumor can have different mutations in different patients, precluding a one-size-fits-all approach. The process involves isolating genetic material from a patient's removed tumor and blood to identify cancer-specific mutations.

“

Instead of one mass-produced drug, we will likely move towards universal technology platforms like mRNA, which will allow for combination therapies for specific patients.